Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537563 · ClinicalTrials.gov registry record · Phase 3
AMS VS MOXI Ketek vs Avelox in AMS
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT00537563: Completed Phase 3 study, sponsored by Sanofi.
NCT00537563 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 351 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00537563, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
Interventions
- DRUG Telithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00537563 record still lists
NCT00537563 is an interventional study that assigns participants to a tested intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which Telithromycin is the first listed.
NCT00537563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00537563 about?
NCT00537563 is a clinical study titled "AMS VS MOXI Ketek vs Avelox in AMS". Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.
What is the current status of trial NCT00537563?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2002-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00537563?
The interventions under investigation include: Telithromycin (DRUG).
Who is sponsoring clinical trial NCT00537563?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00537563's enrollment target sits among peer trials
351 1033rd of 2000 higher than 967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia